Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Enzalutamide Plus Abiraterone May Have Higher Response Rate in mCRPC Than Either Agent Alone

October 1st 2013

Co-targeting metastatic castrate resistant prostate cancer with the combination of enzalutamide plus abiraterone acetate may circumvent the compensatory mechanisms observed with either agent alone and lead to more profound suppression of androgen signaling.

AUA Issues Recommendations for PSA Screening in Prostate Cancer Detection

September 27th 2013

At a time of controversy regarding the value of PSA screening in the early detection of prostate cancer, the AUA has issued a new clinical guideline on the subject and launched an educational campaign designed to share the information with urologists and their patients.

Dr. Shore Comments on the Approval of Radium-223

September 19th 2013

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the approval of radium-223 for patients with bone metastases from prostate cancer.

New Data May Dispel Safety Concerns With 5-ARI Use in Prostate Cancer Prevention

September 19th 2013

The Prostate Cancer Prevention Trial, conducted from January 1997 to February 2003, demonstrated that the 5Î±-reductase inhibitor (5-ARI) finasteride reduced the risk of developing prostate cancer in men being regularly screened for the disease

Herbal Supplement Could Outperform Observation in Some Patients With Recurrent Prostate Cancer

September 18th 2013

A cocktail of herbs and vitamins lowered PSA in more than a third of patients with biochemically recurrent prostate cancer, and thus may be a good alternative to observation in this population.

Ipilimumab Fails to Prolong Survival in mCRPC

September 12th 2013

A phase III trial examining the anti-CTLA-4 immune checkpoint inhibitor ipilimumab in men with metastatic castration-resistant prostate cancer failed to meet its primary endpoint of prolongation in overall survival.

Updated Phase III Data Show Radium-223 Significantly Improves Survival, Extends Time to First SRE

September 10th 2013

An updated analysis of the results of a phase III clinical trial showed that radium-223 dichloride (Xofigo) significantly improved overall survival and delayed time to the first skeletal-related event in patients with metastatic prostate cancer.

Dr. Gulley Discusses Vaccine Responses

September 10th 2013

James L. Gulley, MD, PhD, Head, Clinical Trials Group, Deputy Laboratory Chief, National Cancer Institute, discusses measuring response to vaccines.

Dr. Crawford Compares Degarelix and LHRH Agonists

September 9th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses research that led to the 2008 approval of degarelix as a treatment for men with prostate cancer.

Dr. Vogelzang Discusses the Prostate Health Cocktail

September 5th 2013

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, professor of medicine at the University of Nevada School of Medicine, describes the Prostate Health Cocktail.

Novel Drug Studies Yield Biomarker Candidates for Prostate Cancer Bone Turnover

September 4th 2013

Prostate cancer has a propensity to metastasize to bone. High turnover ultimately results in a net loss of bone tissue; prostate cancer treatment contributes to the loss of bone integrity, as androgen- deprivation therapy often causes abnormally low bone density

Dr. Sartor on Progress for the Treatment of Prostate Cancer

September 3rd 2013

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, discusses the recent progress for the treatment of prostate cancer.

Dr. Shore on Radium-223 Patient Considerations

August 26th 2013

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.

Advances in Prostate Cancer Treatment Highlighted at ASCO

August 19th 2013

At the 2013 ASCO Annual Meeting, researchers presented the latest developments with enzalutamide, radium-223, and abiraterone acetate as treatments for patients with advanced prostate cancer.

Impact of Abiraterone Evident in New AUA Guidelines for mCRPC

August 15th 2013

Amid a flurry of new drug approvals, the AUA has issued its first set of guidelines for the management of patients with mCRPC, which included an extensive role for abiraterone acetate at several stages of the disease.

Isoform Test Tops PSA, fPSA for Cancer Detection

August 2nd 2013

An assay based on a prostate-specific antigen isoform performed significantly better than did conventional PSA measures for detecting prostate cancer and identifying histopathologically aggressive cancers.

Some Prostate Cancers Unaffected, Others Prevented With 5ARIs

July 29th 2013

Investigators say they have found no association between the use of 5-alpha-reductase inhibitors (5ARIs) and the risk of developing high-grade or lethal prostate cancer.

Prostate Cancer Gene Test Could Boost Active Surveillance

July 25th 2013

An assay based on tumor genetics showed potential for stratifying risk in prostate cancer patients and aiding selection of men for active surveillance.

Dr. Shore on Degarelix Versus LHRH Agonists

July 24th 2013

Neal D. Shore, MD, FACS, discusses an analysis of degarelix and luteinising hormone-releasing hormone (LHRH) agonists in prostate cancer.

Dr. George on Radium-223 in Combinations for mCRPC

July 17th 2013

Daniel J. George, MD, from the Duke Cancer Institute, discusses the potential to incorporate radium-223 into combination strategies to treat patients with metastatic castation-resistant prostate cancer.